Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
41 /100
MEDIUM RISK
Score updated Aug 28, 2026

DNTH — Dianthus Therapeutics, Inc. Dilution Risk Tracker

Track DNTH dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track DNTH — Get alerts when the score changes →

As of August 28, 2026, Dianthus Therapeutics, Inc. (DNTH) has a DilutionWatch DilutionScore of 41/100, rated MEDIUM dilution risk. Dianthus Therapeutics, Inc. has a market capitalization of $5.08B, 55.93M shares outstanding, 243 institutional holders tracked. Stored dilution-related fields include shelf registration capacity of $600.00M, ATM program capacity of $100.10M.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
0
📊 Float Risk
10
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

Watch
Minor dilution signals detected
model est. 19%
💰 Capital Raise model 38%
• Active shelf registration ($600M, 12% of market cap)
• Active ATM program with $100M remaining capacity
🔔 Track DNTH — Get forecast alerts →

Market Data

Market Cap$5.08B
Shares Outstanding55.93M
Float54.60M
Cash$886.81M
Debt$1.36M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 40.5% shares (2026Q1 vs prior)
243 institutional holders · 69.42M shares
#1 FMR LLC 7.77M shares
#2 Avidity Partners Management LP 4.21M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 4.06M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest8.38M
Days to Cover9.5
% of Float15.3%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL WARRANT 2025-12-31
xbrl XBRL CONVERTIBLE 2023-12-31
4 INSIDER TRANSACTION 2026-03-13
4 INSIDER TRANSACTION 2026-03-13
4 INSIDER TRANSACTION 2026-03-13
Full SEC filing analysis available with free account

Recent News

No recent news

Factual DNTH Dilution Snapshot

Dianthus Therapeutics, Inc. (DNTH) has a DilutionScore of 41/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track DNTH Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking DNTH — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for DNTH
DNTH FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.